Table 3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

Table 3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

<p>TRAEs (reported as PTs) in ≥20% of patients, grade ≥3 TRAEs in ≥5% of patients, and AESIs in ≥10% of patients in the dose-expansion phase.</p>

Sábháilte in:

Sonraí bibleagrafaíochta
Príomhchruthaitheoir:	Kristoffer Staal Rohrberg (15009138) (author)
Rannpháirtithe:	Juanita S. Lopez (22687839) (author), Mohammed M. Milhem (15352499) (author), Christian U. Blank (14850778) (author), Irene Reijers (22687842) (author), Fiona Thistlethwaite (22687845) (author), Ruth Plummer (15028641) (author), Sarina A. Piha-Paul (15294428) (author), Pasi A. Jänne (14954872) (author), Elaine Shum (14955138) (author), Heather M. Shaw (22687848) (author), Philip R. Debruyne (20432881) (author), Cristopher Lao (22687851) (author), Jean-Francois Baurain (15031089) (author), Jennifer H. Choe (15052775) (author), Eelke Gort (17740951) (author), Yujie Zhao (22687854) (author), Guy Jerusalem (15017648) (author), Patrick Schöffski (15013461) (author), Andrew William Chen (22687857) (author), Eric A. Cohen (15017996) (author), Walter C. Mankowski (22687860) (author), Leonid Roshkovan (22687863) (author), Sharyn I. Katz (22687866) (author), Despina Kontos (15018005) (author), Lauren K. Brady (22687869) (author), Mohammed Qutaish (22687872) (author), Patricia Garrido Castro (22687875) (author), Nora Pencheva (22687878) (author), Gaurav Bajaj (22687881) (author), Yali Fu (22687884) (author), Kristian Windfeld (22687887) (author), Panagiota Reiter (22687890) (author), Maria Jure-Kunkel (15117740) (author), Brandon W. Higgs (15035279) (author), Katayoun I. Amiri (22687893) (author), Tahamtan Ahmadi (22687896) (author), Ulf Forssmann (22687899) (author), Suresh S. Ramalingam (14951413) (author), Ignace Vergote (15027870) (author)
Foilsithe / Cruthaithe:	2025
Ábhair:	Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Immunology Antibodies/immunoconjugates Lung Cancer Melanoma Ovarian Cancer Sarcomas
Clibeanna:	Cuir clib leis Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!

Míreanna comhchosúla

Figure 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
de réir: Kristoffer Staal Rohrberg (15009138)
Foilsithe / Cruthaithe: (2025)

Figure 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
de réir: Kristoffer Staal Rohrberg (15009138)
Foilsithe / Cruthaithe: (2025)

Figure S1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
de réir: Kristoffer Staal Rohrberg (15009138)
Foilsithe / Cruthaithe: (2025)

Figure S2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
de réir: Kristoffer Staal Rohrberg (15009138)
Foilsithe / Cruthaithe: (2025)

Figure S3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
de réir: Kristoffer Staal Rohrberg (15009138)
Foilsithe / Cruthaithe: (2025)

Table 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
de réir: Kristoffer Staal Rohrberg (15009138)
Foilsithe / Cruthaithe: (2025)

Table 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
de réir: Kristoffer Staal Rohrberg (15009138)
Foilsithe / Cruthaithe: (2025)

Table 4 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
de réir: Kristoffer Staal Rohrberg (15009138)
Foilsithe / Cruthaithe: (2025)

Suppl Fig 1 from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma
de réir: Julio C. Chavez (15181310)
Foilsithe / Cruthaithe: (2025)

Suppl Fig 2 from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma
de réir: Julio C. Chavez (15181310)
Foilsithe / Cruthaithe: (2025)

Suppl Fig 3 from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma
de réir: Julio C. Chavez (15181310)
Foilsithe / Cruthaithe: (2025)

Figure S1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
de réir: Niklas Klümper (15048887)
Foilsithe / Cruthaithe: (2025)

Supplementary Data TS1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
de réir: Niklas Klümper (15048887)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
de réir: Ulka N. Vaishampayan (15051039)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
de réir: Ulka N. Vaishampayan (15051039)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure S3 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
de réir: Ulka N. Vaishampayan (15051039)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
de réir: Ulka N. Vaishampayan (15051039)
Foilsithe / Cruthaithe: (2025)

Figure S1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
de réir: Martina S.J. McDermott (15206951)
Foilsithe / Cruthaithe: (2025)

Figure S2 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
de réir: Martina S.J. McDermott (15206951)
Foilsithe / Cruthaithe: (2025)

Figure S3 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
de réir: Martina S.J. McDermott (15206951)
Foilsithe / Cruthaithe: (2025)

Figure S4 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
de réir: Martina S.J. McDermott (15206951)
Foilsithe / Cruthaithe: (2025)

Figure S5 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
de réir: Martina S.J. McDermott (15206951)
Foilsithe / Cruthaithe: (2025)

Figure S6 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
de réir: Martina S.J. McDermott (15206951)
Foilsithe / Cruthaithe: (2025)

Figure S7 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
de réir: Martina S.J. McDermott (15206951)
Foilsithe / Cruthaithe: (2025)

Figure S8 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
de réir: Martina S.J. McDermott (15206951)
Foilsithe / Cruthaithe: (2025)

Supplemental Tables 1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
de réir: Martina S.J. McDermott (15206951)
Foilsithe / Cruthaithe: (2025)

Table S1 from Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary Tumors and Metastases
de réir: Noor Jailkhani (16015810)
Foilsithe / Cruthaithe: (2025)

Table S2 from Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary Tumors and Metastases
de réir: Noor Jailkhani (16015810)
Foilsithe / Cruthaithe: (2025)

Table S3 from Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary Tumors and Metastases
de réir: Noor Jailkhani (16015810)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S2 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma
de réir: John A. Ligon (15024477)
Foilsithe / Cruthaithe: (2025)

Figure S1 from A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma <i>In Situ</i> of the Bladder
de réir: Roger Li (17078665)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure 1 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
de réir: Dwight H. Owen (15034782)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
de réir: Dwight H. Owen (15034782)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure 3 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
de réir: Dwight H. Owen (15034782)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure 4 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
de réir: Dwight H. Owen (15034782)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
de réir: Dwight H. Owen (15034782)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure S1 from First-in-Maintenance Therapy for Localized High-Grade Osteosarcoma: An Open-Label Phase I/II Trial of the Anti–PD-L1 Antibody ZKAB001
de réir: Yan Zhou (15053225)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure 1 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
de réir: Tom Wei-Wu Chen (15053003)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure 2 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
de réir: Tom Wei-Wu Chen (15053003)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure 3 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
de réir: Tom Wei-Wu Chen (15053003)
Foilsithe / Cruthaithe: (2025)

Cannot write session to /tmp/vufind_sessions/sess_114iapsi325vjfeto4fvdi07oi